U.S. market Closed. Opens in 8 hours 45 minutes

MLYS | Mineralys Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 12.52 - 14.18
52 Week Range 6.38 - 16.91
Beta 1.44
Implied Volatility 141.56%
IV Rank 10.73%
Day's Volume 511,342
Average Volume 163,861
Shares Outstanding 49,768,670
Market Cap 671,379,358
Sector Healthcare
Industry Biotechnology
IPO Date 2023-02-10
Valuation
Profitability
Growth
Health
P/E Ratio -4.08
Forward P/E Ratio N/A
EPS -3.31
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 28
Country USA
Website MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
*Chart delayed
Analyzing fundamentals for MLYS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MLYS Fundamentals page.

Watching at MLYS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on MLYS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙